BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9

• Press Releases

  Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer

  June 2, 2026

   · 

  3 min read
• Press Releases

  Single Blood Test Simultaneously Captures Immune, Stromal, and Tumor Signals Linked to Immunotherapy Response and Resistance in Sarcoma

  June 2, 2026

   · 

  4 min read
• Press Releases

  Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

  June 2, 2026

   · 

  5 min read
• Press Releases

  IAVI to Advance Vaccine Candidate for Bundibugyo Virus, Receives Funding from CEPI

  June 2, 2026

   · 

  4 min read
• Press Releases

  Charles River Laboratories to Present at William Blair and Jefferies Conferences 2026

  June 2, 2026

   · 

  1 min read
• Press Releases

  GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations

  June 2, 2026

   · 

  14 min read
• Press Releases

  Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

  June 2, 2026

   · 

  7 min read
• Press Releases

  Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

  June 2, 2026

   · 

  14 min read
• Press Releases

  Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

  June 2, 2026

   · 

  13 min read
• Press Releases

  IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

  June 2, 2026

   · 

  10 min read